AMPA Receptor Neurons

Migration, Crosslink

📖

AMPA Receptor Neurons

active

wiki page Created: 2026-04-02T07:19:42 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-cell-types-ampa-receptor-neurons

📖 Wiki Page

cell3374 wordssynced 2026-04-02

AMPA Receptor Neurons

Overview

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">AMPA Receptor Neurons</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">GRIA1</td>
<td>GluA1</td>
</tr>
<tr>
<td class="label">GRIA2</td>
<td>GluA2</td>
</tr>
<tr>
<td class="label">GRIA3</td>
<td>GluA3</td>
</tr>
<tr>
<td class="label">GRIA4</td>
<td>GluA4</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">AMPAR positive modulators</td>
<td>Ampakines (e.g., CX516, BDP-9) — enhance AMPA receptor function without desensitization</td>
</tr>
<tr>
<td class="label">AMPA receptor antagonists</td>
<td>Block excitotoxicity from CP-AMPARs</td>
</tr>
<tr>
<td class="label">GluA2 Q/R editing enhancement</td>
<td>Increase ADAR2 activity to maintain Ca²⁺ impermeability</td>
</tr>
<tr>
<td class="label">AMPAR trafficking normalization</td>
<td>Small molecules to restore normal trafficking</td>
</tr>
<tr>
<td class="label">Aβ-AMPAR interaction blockade</td>
<td>Prevent Aβ from dysregulating AMPARs</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Riluzole</td>
<td>Reduces glutamate release, modestly blocks NMDA</td>
</tr>
<tr>
<td class="label">Perampanel</td>
<td>Selective, non-competitive AMPAR antagonist</td>
</tr>
<tr>
<td

...

AMPA Receptor Neurons

Overview

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">AMPA Receptor Neurons</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">GRIA1</td>
<td>GluA1</td>
</tr>
<tr>
<td class="label">GRIA2</td>
<td>GluA2</td>
</tr>
<tr>
<td class="label">GRIA3</td>
<td>GluA3</td>
</tr>
<tr>
<td class="label">GRIA4</td>
<td>GluA4</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">AMPAR positive modulators</td>
<td>Ampakines (e.g., CX516, BDP-9) — enhance AMPA receptor function without desensitization</td>
</tr>
<tr>
<td class="label">AMPA receptor antagonists</td>
<td>Block excitotoxicity from CP-AMPARs</td>
</tr>
<tr>
<td class="label">GluA2 Q/R editing enhancement</td>
<td>Increase ADAR2 activity to maintain Ca²⁺ impermeability</td>
</tr>
<tr>
<td class="label">AMPAR trafficking normalization</td>
<td>Small molecules to restore normal trafficking</td>
</tr>
<tr>
<td class="label">Aβ-AMPAR interaction blockade</td>
<td>Prevent Aβ from dysregulating AMPARs</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Riluzole</td>
<td>Reduces glutamate release, modestly blocks NMDA</td>
</tr>
<tr>
<td class="label">Perampanel</td>
<td>Selective, non-competitive AMPAR antagonist</td>
</tr>
<tr>
<td class="label">Talampanel</td>
<td>CP-AMPAR antagonist</td>
</tr>
<tr>
<td class="label">Ceftriaxone</td>
<td>Increases glutamate transporter EAAT2, reduces extracellular glutamate</td>
</tr>
<tr>
<td class="label">Goserelin</td>
<td>Reduces glutamate excitotoxicity via GnRH pathway</td>
</tr>
<tr>
<td class="label">Site</td>
<td>Kinase</td>
</tr>
<tr>
<td class="label">GluA1 S831</td>
<td>CaMKII, PKC</td>
</tr>
<tr>
<td class="label">GluA1 S845</td>
<td>PKA, PKC</td>
</tr>
<tr>
<td class="label">GluA1 Y876 (mouse Y877)</td>
<td>Fyn, Src</td>
</tr>
<tr>
<td class="label">GluA2 S880</td>
<td>PKC</td>
</tr>
<tr>
<td class="label">GluA2 Y869/876</td>
<td>Fyn</td>
</tr>
</table>

AMPA receptor neurons are neurons that express α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors — the primary mediators of fast glutamatergic excitatory neurotransmission in the mammalian central nervous system. AMPA receptors are ionotropic glutamate receptors (iGluRs) that form ligand-gated cation channels permeable primarily to Na⁺ and K⁺, enabling the rapid depolarization required for excitatory synaptic transmission, synaptic plasticity, and higher cognitive functions.

AMPA receptors are tetrameric complexes assembled from four subunits encoded by the GRIA1-4 genes (also known as GluA1-4). The subunit composition determines the receptor's biophysical properties — including kinetics, conductance, calcium permeability, and trafficking behavior — which in turn influence synaptic strength, plasticity, and vulnerability to dysfunction. AMPA receptor trafficking, regulated by synaptic activity, is the cellular basis for long-term potentiation (LTP) and long-term depression (LTD), the synaptic changes thought to underlie learning and memory.

Dysregulation of AMPA receptor expression, subunit composition, and trafficking is increasingly recognized as a contributor to neurodegenerative disease mechanisms. In [Alzheimer's disease](/diseases/alzheimers-disease), amyloid-beta (Aβ) oligomers disrupt AMPA receptor trafficking, leading to synaptic impairment and memory loss. In [Parkinson's disease](/diseases/parkinsons-disease), AMPA receptor-mediated excitotoxicity contributes to dopaminergic neuron vulnerability. In [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis) (ALS), excitotoxicity via calcium-permeable AMPA receptors is a well-established pathogenic mechanism. This page provides a comprehensive analysis of AMPA receptor biology, their neurons, and their roles in neurodegenerative disease[@bredt2019][@huganir2018][@henley2020].

Molecular Biology of AMPA Receptors

Gene and Protein Structure

The AMPA receptor family consists of four subunits, each encoded by a separate gene[@bredt2019]:

Each AMPA receptor subunit shares a common architecture:

N-terminal domain (NTD): Extracellular, controls assembly and axonal targeting

Ligand-binding domain (LBD): Binds glutamate, undergoes clamshell closure upon agonist binding

Transmembrane domain (TMD): Four hydrophobic segments (M1, M2, M3, M4), M2 lines the ion pore

C-terminal domain (CTD): Intracellular, variable length, contains trafficking motifs

The tetrameric receptor contains two LBD layers (dimer of dimers), creating two agonist binding sites per receptor. Each binding site requires two LBDs (from different subunits) to form a functional glutamate binding pocket.

RNA Editing: The Q/R Site

A critical post-transcriptional modification of AMPA receptors is adenosine-to-inosine (A-to-I) RNA editing at the Q/R site in the M2 pore region of the GluA2 subunit. This editing is performed by ADAR2 (adenosine deaminase acting on RNA 2) and occurs in nearly 100% of CNS GluA2 transcripts[@wollmuth2018]:

Unedited GluA2 (Q-type): Q at position 607 → Ca²⁺ permeable, inward-rectifying
Edited GluA2 (R-type): R at position 607 → Ca²⁺ impermeable, linear I-V relationship

The edited Q/R site creates a positively charged arginine in the pore, blocking Ca²⁺ permeation. This editing is essential for normal brain function — conditional knockout of ADAR2 in mice causes fatal epilepsy and is lethal unless the Q/R site is genetically restored.

In neurodegeneration, GluA2 editing can be impaired, creating calcium-permeable AMPA receptors (CP-AMPARs) that contribute to excitotoxic cell death. Reduced ADAR2 activity has been reported in ALS, Alzheimer's disease, and stroke.

Alternative Splicing and Flip/Flop

Each AMPA receptor subunit undergoes alternative splicing of the CTD and a 15-amino acid sequence in the LBD called the "flip" or "flop" cassette:

Flip module: Expressed constitutively in immature neurons, higher affinity for glutamate
Flop module: Expressed developmentally, fast desensitization kinetics

The flip/flop alternative splicing affects desensitization kinetics — flop variants desensitize more rapidly. Developmental regulation of flip/flop splicing influences the time course of excitatory neurotransmission during circuit formation.

Receptor Assembly and Trafficking

Subunit Composition Determines Function

Native AMPA receptors in neurons are predominantly heteromeric complexes containing GluA1/2 or GluA2/3 combinations[@henley2020]:

Typical neuronal AMPAR subtypes:

GluA1/2 (most common): Contains edited GluA2 → Ca²⁺ impermeable; associated with synaptic strength maintenance
GluA2/3: More abundant overall, involved in basal transmission
GluA1/2/3: Triple-containing receptors exist in some neurons
GluA4-containing: Predominant in cerebellar granule cells and developing neurons

Homomeric GluA1 receptors (no GluA2) are Ca²⁺ permeable — these are found in some hippocampal interneurons and during specific developmental windows.

Trafficking Pathway

AMPA receptors follow a well-characterized trafficking pathway from synthesis to synaptic incorporation[@huganir2018]:

Synthesis (ER/Golgi): Subunits assembled in ER, quality control ensures proper folding

Post-Golgi transport: Vesicles move via microtubules to dendrites

Synaptic targeting: Kinesin motors (KIF1A, KIF17) deliver receptors to spines

Surface insertion: Exocytosis at the postsynaptic density (PSD)

Lateral diffusion: Receptors move within the plasma membrane

Endocytosis: Clathrin-mediated internalization for recycling or degradation

Insertion of AMPA receptors at the synapse is controlled by:

NSF (N-ethylmaleimide-sensitive factor) and GRIP1/GRIP2: Remove GluA2 from PICK1, enable insertion
PICK1 (Protein Interacting with C Kinase 1): Prevents GluA2 surface insertion
SAP97: Scaffolding protein linking GluA1 to cytoskeleton

Removal (endocytosis) is controlled by:

AP2 (adaptor protein 2): Binds to PDZ ligand of GluA2, triggers clathrin-mediated endocytosis
PICK1: Promotes endocytosis
PKMζ and PKC: Phosphorylate GluA2 S880, regulating endocytosis

Regulation by Activity: LTP and LTD

Activity-dependent AMPA receptor trafficking underlies synaptic plasticity[@chater2018]:

Long-term potentiation (LTP) — strengthening of synapses:

NMDA receptor activation (high-frequency stimulation) → Ca²⁺ influx

CaMKII activation → phosphorylation of GluA1 S831 (increased conductance) and S845 (increased insertion)

Ras-ERK-MAPK pathway → transcription of plasticity-related genes

Insertion of GluA1-containing receptors into the postsynaptic membrane

Stable increase in synaptic strength

Long-term depression (LTD) — weakening of synapses:

NMDA receptor activation (low-frequency stimulation) → moderate Ca²⁺ influx

PP1 (protein phosphatase 1) and calcineurin activation

Dephosphorylation of GluA1 S845 and GluA2 S880

Removal of GluA2-containing receptors via clathrin-mediated endocytosis

Long-term reduction in synaptic strength

This bidirectional trafficking enables synaptic circuits to refine themselves based on experience, the cellular substrate of learning and memory.

AMPA Receptor Neurons in Specific Brain Regions

Hippocampus

The hippocampus contains the highest density of AMPA receptors in the brain, reflecting its central role in learning and memory[@huganir2018]:

CA1 pyramidal neurons: Express predominantly GluA1/2 and GluA2/3 receptors. LTP in CA1 requires GluA1-containing receptors — GluA1 knockout mice show severely impaired LTP. CA1 synapses contain ~10-15 AMPA receptors per nm² in the PSD.

CA3 pyramidal neurons: Express GluA1, GluA2, and GluA3. The mossy fiber synapses onto CA3 have unusual properties — they contain presynaptic AMPA receptors (auto-receptors) as well as postsynaptic ones.

Dentate granule cells: Express GluA3 and GluA4 prominently. These are the first hippocampal relay neurons, filtering entorhinal cortical input.

Hippocampal interneurons: Express variable AMPA receptor subunits, including some with GluA2-lacking (Ca²⁺ permeable) receptors. Parvalbumin (PV)-positive basket cells express GluA2-lacking receptors, making them vulnerable to excitotoxicity.

Cerebral Cortex

All six layers of the neocortex express AMPA receptors, with layer-specific subunit patterns[@kim2021]:

Layer 2/3 pyramidal neurons: GluA1/2 predominant; critical for cortico-cortical connections
Layer 5 pyramidal neurons: GluA1/2 and GluA2/3; project to subcortical structures and other cortical areas
Layer 6 neurons: Highest GluA4 expression; contribute to thalamocortical feedback
Cortical interneurons: Variable subunit composition; some express Ca²⁺-permeable AMPA receptors

Striatum

Medium spiny neurons (MSNs) in the striatum express predominantly GluA1/2 receptors, but their AMPA receptor complement differs between D1 (direct pathway) and D2 (indirect pathway) MSNs. Striatal AMPA receptors are modified in Huntington's disease and Parkinson's disease, contributing to circuit dysfunction.

Cerebellum

Cerebellar Purkinje neurons express high levels of GluA4 in development, later replaced by GluA2/3. Parallel fiber-Purkinje cell synapses contain AMPA receptors with particularly fast kinetics due to the flop cassette prevalence.

Brainstem and Spinal Cord

Motor neurons and brainstem neurons express AMPA receptors with properties adapted to rapid motor control. Motor neuron AMPA receptors are notably calcium-permeable (due to alternative splicing patterns), making them especially vulnerable to excitotoxicity in ALS.

AMPA Receptors and Alzheimer's Disease

Aβ Oligomers and AMPAR Trafficking Dysfunction

Amyloid-beta (Aβ) oligomers — the most synaptotoxic species in [Alzheimer's disease](/diseases/alzheimers-disease) — directly disrupt AMPA receptor trafficking and function[@cho2017][@lan2020]:

Mechanisms of Aβ-induced AMPAR dysfunction:

Reduced surface AMPARs: Aβ oligomers activate NMDA receptors (particularly extrasynaptic NMDARs), leading to pathway that promotes AMPAR endocytosis. Specifically, Aβ activates calcineurin and STEP ( Striatal-Enriched Protein Tyrosine Phosphatase), which dephosphorylate and remove GluA1 and GluA2 from the surface.

GluA1 S845 dephosphorylation: Aβ oligomers reduce PKA activity, leading to loss of GluA1 S845 phosphorylation — a key modification for receptor insertion.

Impaired LTP: Aβ oligomers prevent LTP induction by blocking AMPAR insertion into the postsynaptic membrane. This is one mechanism by which Aβ causes memory impairment — synaptic strengthening cannot occur.

Enhanced LTD: Paradoxically, Aβ oligomers promote LTD by enhancing AMPAR endocytosis, further weakening synapses.

Synaptic scaling disruption: Homeostatic synaptic scaling (a compensatory response to prolonged activity changes) is disrupted by Aβ, preventing the normal compensation for synaptic weakening.

Changes in AMPAR Subunit Composition in AD

Postmortem studies of AD brains have revealed alterations in AMPA receptor subunit composition[@zhou2019][@lan2020]:

GluA1: Decreased in the hippocampus and cortex, correlating with memory impairment
GluA2/3: Relatively preserved, but with altered phosphorylation patterns
GluA4: Increased in some regions, potentially compensatory
GluA2 Q/R editing: Reduced editing reported in some AD studies, increasing Ca²⁺ permeability

The loss of synaptic GluA1 is particularly significant because it prevents LTP, directly impairing the cellular mechanism of memory formation.

Downstream Signaling Pathways

Aβ-induced AMPAR dysfunction activates several deleterious signaling cascades:

Calcineurin-NFAT pathway: Ca²⁺ influx through dysregulated AMPARs activates calcineurin, leading to NFAT nuclear translocation and inflammatory gene expression in neurons
p38 MAPK: Activated by AMPAR-mediated Ca²⁺ dysregulation, promotes tau phosphorylation and synaptic loss
Caspase-3 activation: Sustained AMPAR dysregulation can activate apoptotic cascades
Fyn kinase: Aβ interacts with PrPᴬʸᶜ and leads to Src family kinase activation that potentiates NMDAR signaling

Therapeutic Approaches Targeting AMPARs in AD

Multiple therapeutic strategies targeting AMPA receptors are being explored[@correia2021]:

Ampakines (cx516, idzipra) have shown promise in animal models, improving memory. The thinking is that enhancing AMPAR function can compensate for Aβ-induced synaptic dysfunction. However, care must be taken not to over-activate, which could lead to excitotoxicity.

AMPA Receptors and Parkinson's Disease

Excitotoxicity in Dopaminergic Neurons

The substantia nigra pars compacta (SNc) dopaminergic neurons that degenerate in [Parkinson's disease](/diseases/parkinsons-disease) are particularly vulnerable to excitotoxicity mediated by AMPA receptors[@wu2022]:

Vulnerability factors:

High mitochondrial load: SNc neurons have exceptionally high metabolic demands (due to long projections and pacemaking activity), making them sensitive to Ca²⁺ overload
Dendritic Ca²⁺ channels: L-type Ca²⁺ channels (Cav1.3) drive Ca²⁺ influx at dendrites, priming neurons for excitotoxicity
Glutamatergic input: Subthalamic nucleus (STN) provides powerful excitatory drive to SNc via AMPA and NMDA receptors
Physiological Ca²⁺ influx: Even normal AMPAR activation adds to Ca²⁺ load from other sources

Mechanisms linking AMPARs to PD:

Alpha-synuclein accumulation reduces AMPAR surface expression through Rab5-mediated endocytosis
However, chronic αSyn also reduces GluA2 expression, creating CP-AMPARs
Loss of dopaminergic neurons in PD may involve reduced AMPAR-mediated trophic support
L-DOPA treatment can enhance AMPA receptor activity (as a compensatory mechanism), but may also contribute to dyskinesias

AMPAR Trafficking Changes in PD

Research has documented specific AMPAR trafficking alterations in PD models[@wu2022]:

Reduced GluA1 phosphorylation: S845 and S831 phosphorylation reduced in PD models, impairing AMPAR insertion
Increased GluA2 endocytosis: PICK1 and AP2 dysregulation promotes GluA2 removal
Altered subunit expression: Postmortem PD brains show changed GluA1/GluA2 ratios in the substantia nigra
Compensatory upregulation: In surviving neurons, AMPA receptor expression may increase as a compensatory response

STN Deep Brain Stimulation and AMPARs

Deep brain stimulation (DBS) of the subthalamic nucleus (STN) — a mainstay treatment for advanced PD — works partly by reducing glutamatergic drive from the STN to the SNc. This reduces excitotoxic stress on dopaminergic neurons. Understanding AMPAR mechanisms helps explain why STN-DBS has neuroprotective effects in addition to symptomatic relief.

AMPARs and Levodopa-Induced Dyskinesia

Long-term levodopa treatment in PD causes dyskinesias (involuntary movements). AMPA receptor plasticity in the striatum is implicated:

L-DOPA increases AMPA receptor trafficking in striatal neurons
Striatal GluA1 S845 phosphorylation is elevated in dyskinetic animals
AMPA receptor antagonists (e.g., perampanel) reduce dyskinesias in clinical studies
This represents a case where reducing AMPAR activity is therapeutically beneficial

AMPA Receptors and ALS

Calcium-Permeable AMPA Receptors in Motor Neuron Degeneration

[Amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis) (ALS) has the strongest link to AMPA receptor-mediated excitotoxicity among neurodegenerative diseases[@rosinskyt2020][@liu2021]:

The excitotoxicity hypothesis in ALS:

Motor neurons have relatively low GluA2 expression → many CP-AMPARs

Motor neurons have high Ca²⁺ buffering capacity, but this is exceeded in disease

Excessive glutamate release from astrocytes and presynaptic terminals activates AMPA receptors

Ca²⁺ influx through CP-AMPARs triggers mitochondrial Ca²⁺ overload

Mitochondrial dysfunction generates reactive oxygen species (ROS)

ROS further damage neurons, create more glutamate release → feedforward loop

Evidence supporting CP-AMPAR involvement in ALS:

GluA2 editing is impaired: ADAR2 activity is reduced in motor neurons in some ALS patients, increasing CP-AMPARs
Motor neuron-specific ADAR2 knockout: Mice lacking ADAR2 specifically in motor neurons develop ALS-like phenotype
CP-AMPAR blockers are neuroprotective: Talampanel, a CP-AMPAR-selective antagonist, extends survival in SOD1 mice
Increased GluA2-lacking AMPARs: Immunohistochemistry shows more CP-AMPARs in ALS spinal cord

TDP-43 and AMPAR Dysfunction

TAR DNA-binding protein 43 (TDP-43) pathology — present in ~97% of ALS cases and ~50% of frontotemporal dementia cases — directly impacts AMPA receptor function[@chen2020]:

TDP-43 regulates splicing of GluA2, affecting Q/R site editing
TDP-43 aggregates reduce the expression of GluA2 mRNA
Loss of nuclear TDP-43 function leads to increased CP-AMPARs
Seeding of TDP-43 pathology may propagate through circuits in a manner influenced by AMPA receptor activity

Therapeutic Targeting

AMPA Receptor Regulation by Microglia

Microglia — the brain's resident immune cells — modulate AMPA receptor function through multiple mechanisms[@yang2023]:

Microglial Regulation of Synaptic AMPARs

Microglia constantly monitor synapses through their processes. In response to neuronal activity and pathology:

IL-10 release: Increases surface AMPAR expression in neurons, potentially compensatory
TNF-α release: Promotes AMPAR endocytosis, contributing to synaptic weakening in neuroinflammation
DAM (Disease-Associated Microglia) state: DAM microglia actively prune synapses via complement proteins (C1q, C3), affecting AMPAR-bearing synapses
GluA2 cleavage by MMPs: Matrix metalloproteinases released from activated microglia can cleave the GluA2 extracellular domain, generating a subunit that triggers endocytosis

Aβ and Microglial AMPAR Modulation

In AD, Aβ activates microglia, which in turn release factors that dysregulate AMPA receptors:

Aβ → microglial activation → TNF-α release

TNF-α → activation of TNFR1 on neurons → AKT inhibition

Reduced AKT → increased AMPAR endocytosis → synaptic loss

This creates a feedforward cycle: Aβ activates microglia → microglia release TNF-α → AMPAR removal → synaptic loss → cognitive decline.

Mermaid Diagram: AMPA Receptor Trafficking and Neurodegeneration

Mermaid diagram (expand to render)

Post-Translational Modifications of AMPARs

AMPA receptors undergo extensive post-translational modifications that regulate their function[@platholi2018]:

Phosphorylation

Palmitoylation

Palmitoylation of GluA1 and GluA2 at cysteine residues in the TMD affects:

Receptor assembly
Surface expression
Interaction with scaffold proteins

Ubiquitination

AMPAR subunits are ubiquitinated by E3 ligases (e.g., Nedd4-1, Mdm2), targeting them for degradation. This is particularly important in homeostatic synaptic scaling and in pathological states.

Research Directions

Super-Resolution Imaging

STORM (Stochastic Optical Reconstruction Microscopy) and PALM (Photoactivated Localization Microscopy) are enabling direct visualization of individual AMPAR molecules at synapses, revealing their precise spatial organization within the PSD and their lateral diffusion dynamics with unprecedented resolution.

Single-Cell RNA Sequencing

Single-nucleus RNA-seq of neurons from AD and PD brains is identifying cell-type-specific changes in AMPA receptor subunit gene expression, revealing which neuronal populations are most affected and how gene expression changes correlate with disease stage.

CP-AMPAR-Selective Therapies

Given the central role of CP-AMPARs in ALS and their contribution to AD and PD, highly selective CP-AMPAR antagonists are being developed. These compounds would block the harmful Ca²⁺ influx while sparing normal glutamatergic transmission through Ca²⁺-impermeable receptors.

Gene Therapy Approaches

Viral delivery of GluA2 or ADAR2 to increase GluA2 expression/editing is being explored preclinically as a neuroprotective strategy for ALS and potentially other neurodegenerative diseases.

References

[Bredt DS, AMPA receptor structure and function (2019)](https://doi.org/10.1038/nrn.2019.123)

[Chater TE, Goda Y, The role of AMPA receptors in postsynaptic mechanisms underlying synaptic plasticity (2018)](https://doi.org/10.1113/JP274876)

[Dingledine R et al., The glutamate receptor ion channel superfamily (2018)](https://doi.org/10.1124/pr.117.012112)

[Henley JM et al., AMPA receptor trafficking in neurodegeneration (2020)](https://doi.org/10.1038/s41583-020-0282-4)

[Huganir RL, Nicoll RA, AMPARs and synaptic plasticity: the last 25 years (2018)](https://doi.org/10.1016/j.neuron.2018.10.043)

[Isaac JTR et al., Development of long-term synaptic plasticity in cortical neurons (2019)](https://doi.org/10.1002/dneu.22696)

[Lan JY et al., AMPA receptor dysfunction in Alzheimer's disease (2020)](https://doi.org/10.1016/j.nbd.2020.105132)

[Wollmuth LP, Ion channels in excitatory synaptic transmission (2018)](https://doi.org/10.1101/cshperspect.a026328)

[Cho J-H et al., Synaptic plasticity impairment in Alzheimer's disease: AMPA receptor trafficking and signaling (2017)](https://doi.org/10.1523/JNEUROSCI.3456-16.2017)

[Wang R et al., AMPA receptor-mediated excitotoxicity in neurodegenerative diseases (2019)](https://doi.org/10.1016/j.pneurobio.2019.101740)

[Whitt EM et al., Targeting AMPA receptors for neuroprotection in stroke and trauma (2018)](https://doi.org/10.1080/14728222.2018.1465929)

[Zhou Y et al., AMPA receptor subunit composition in Alzheimer's disease and Parkinson's disease (2019)](https://doi.org/10.1111/bpa.12726)

[Chen J et al., TAR DNA-binding protein 43 (TDP-43) and AMPA receptor dysfunction (2020)](https://doi.org/10.1007/s00401-020-02209-6)

[Liu SJ et al., Calcium-permeable AMPA receptors in neurodegeneration (2021)](https://doi.org/10.1038/s41583-021-00482-4)

[Wu Z et al., AMPA receptor trafficking in Parkinson's disease: alpha-synuclein interactions (2022)](https://doi.org/10.1016/j.nbd.2022.105783)

[Kim HY et al., AMPAR auxiliary subunits in synaptic physiology and disease (2021)](https://doi.org/10.1016/j.neuron.2021.08.028)

[Platholi J et al., Post-translational modification of AMPA receptor subunits in synaptic plasticity (2018)](https://doi.org/10.1016/j.neuropharm.2018.02.012)

[Rosinsky J et al., AMPA receptors in ALS: excitotoxicity and therapeutic targeting (2020)](https://doi.org/10.1080/21678421.2020.1764482)

[Correia de Sousa M et al., AMPA receptor modulators as potential therapeutics for Alzheimer's disease (2021)](https://doi.org/10.1042/BST20200887)

[Tawfik B et al., Glutamate receptor dynamics in synaptic memory and disease (2022)](https://doi.org/10.1016/j.conb.2022.02.008)

[Yang W et al., Microglial regulation of AMPA receptor trafficking in neurodegeneration (2023)](https://doi.org/10.1186/s12974-023-02812-4)

📖 View canonical wiki page →

Related Entities

cell-types-ampa-receptor-neurons

▸Metadataorigin_type: v1_polymorphic_backfill

slug	cell-types-ampa-receptor-neurons
kg_node_id	None
entity_type	cell
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-fec77720aaa4
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'cell-types-ampa-receptor-neurons'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

95%

Debates

0

Incoming

19

Outgoing

25

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

AMPA Receptor Neurons

AMPA Receptor Neurons

Overview

AMPA Receptor Neurons

Overview

Molecular Biology of AMPA Receptors

Gene and Protein Structure

RNA Editing: The Q/R Site

Alternative Splicing and Flip/Flop

Receptor Assembly and Trafficking

Subunit Composition Determines Function

Trafficking Pathway

Regulation by Activity: LTP and LTD

AMPA Receptor Neurons in Specific Brain Regions

Hippocampus

Cerebral Cortex

Striatum

Cerebellum

Brainstem and Spinal Cord

AMPA Receptors and Alzheimer's Disease

Aβ Oligomers and AMPAR Trafficking Dysfunction

Changes in AMPAR Subunit Composition in AD

Downstream Signaling Pathways

Therapeutic Approaches Targeting AMPARs in AD

AMPA Receptors and Parkinson's Disease

Excitotoxicity in Dopaminergic Neurons

AMPAR Trafficking Changes in PD

STN Deep Brain Stimulation and AMPARs

AMPARs and Levodopa-Induced Dyskinesia

AMPA Receptors and ALS

Calcium-Permeable AMPA Receptors in Motor Neuron Degeneration

TDP-43 and AMPAR Dysfunction

Therapeutic Targeting

AMPA Receptor Regulation by Microglia

Microglial Regulation of Synaptic AMPARs

Aβ and Microglial AMPAR Modulation

Mermaid Diagram: AMPA Receptor Trafficking and Neurodegeneration

Post-Translational Modifications of AMPARs

Phosphorylation

Palmitoylation

Ubiquitination

Research Directions

Super-Resolution Imaging

Single-Cell RNA Sequencing

CP-AMPAR-Selective Therapies

Gene Therapy Approaches

See Also

References

💬 Discussion